Asialoerythropoietin has strong renoprotective effects against ischemia-reperfusion injury in a murine model

Transplantation

Volumn 84, Issue 4, 2007, Pages 504-510

  Okada, Toshie ^a   Sawada, Tokihiko ^a   Kubota, Keiichi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Asialoerythropoietin; Erythropoietin; Ischemia; Kidney; Reperfusion

Indexed keywords

ASIALOERYTHROPOIETIN; CREATININE; ERYTHROPOIETIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BAD; PROTEIN BCL XL; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CLAMP; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; KIDNEY DYSFUNCTION; KIDNEY ISCHEMIA; KIDNEY PARENCHYMA; MOUSE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; SURVIVAL RATE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; ASIALOGLYCOPROTEINS; BCL-ASSOCIATED DEATH PROTEIN; BCL-X PROTEIN; CREATININE; DISEASE MODELS, ANIMAL; ERYTHROPOIETIN; FEMALE; KIDNEY; MICE; MICE, INBRED BALB C; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RANDOM ALLOCATION; REPERFUSION INJURY; SURVIVAL RATE; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 34548155283     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000277672.02783.33     Document Type: Article

References (33)

1. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39: 930.
2. Thakar CV, Liangos O, Yared JP, et al. ARF after open-heart surgery: influence of gender and race. Am J Kidney Dis 2003; 41: 742.
3. Brines M, Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005; 6: 484.
4. Santhanam AV, Katusic ZS. Erythropoietin and cerebral vascular protection: role of nitric oxide. Acta Pharmacol Sin 2006; 27: 1389.
5. Schneider C, Jaquet K, Malisius R, et al. Attenuation of cardiac remodelling by endocardial injection of erythropoietin: Ultrasonic strain-rate imaging in a model of hibernating myocardium. Eur Heart J 2007; 28: 499.
6. Lipsic E, Schoemaker RG, van der Meer P, et al. Protective effects of erythropoietin in cardiac ischemia: From bench to bedside. J Am Coll Cardiol 2006; 48: 2161.
7. Sharples E, Thiemermann C, Yaqoob MM. Mechanism of disease: cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat Clin Practice 2006; 1: 87.
8. Johnson DW, Forman C, Vesey DA. Novel renoprotective actions of erythropoietin: New use for an old hormone. Nephrol 2006; 11: 306.
9. Bahlmann FB, DeGroot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 2003; 64: 1648.
10. Yang CW, Li C, Jung JY, et al. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. FASEB J 2003; 17: 1754.
11. Ates E, Yalcin U, Yilmaz S, et al. Protective effect of erythropoietin on renal ischemia and reperfusion injury. ANZ J Surg 2005; 75: 1100.
12. Sharples EJ, Yaqoob MM. Erythropoietin in experimental acute renal failure. Nephrol 2006; 104: e83.
13. Minamino T, Kitakaze M. New therapeutic application of erythropoietin against ischemic heart diseases. J Pharmacol Sci 2006; 101: 179.
14. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is safe and beneficial. Mol Med 2002; 8: 495.
15. Higuchi M, Oh-eda M, Kuboniwa H, et al. Role of sugar chain in the expression of the biological activity of human erythropoietin. J Biol Chem 1992; 267: 7703.
16. Mennini T, De Paolo M, Bigini P, et al. Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. Mol Med 2006; 12: 153.
17. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 1994; 266: F360.
18. Patel NS, Sharples EJ, Cuzzocrea S, et al. Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney. Kidney Int 2004; 66: 983.
19. Sharples E, Patel N, Brown P, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15: 2115.
20. Imai N, Kawamura A, Tomonoh K, et al. Physicochemical and biological characterization of asialoerythropoietin. Eur J Biochem 1990; 194: 457.
21. Westenfedler C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55: 808.
22. Anagnostou A, Lee ES, Kessimian N, et al. Erythropoietin has a mitogenic and positive chemotactic effect on endothelaial cells. Proc Natl Acad Sci USA 1990; 87: 5978.
23. Maxwell P. HIF-1: An oxygen response system with special relevance to the kidney. J Am Soc Nephrol 2003; 14: 2712.
24. Brines M, Grasso G, Fiordaliso F, et al. Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor. Proc Natl Acad Sci USA 2004; 41: 14907.
25. Kunduzova O, Bianchi P, Pizzinat N, et al. Regulation of JNK/ERK activation, cell apoptosis, and tissue regeneration by monoamine oxidases after renal ischemia-reperfusion. FASEB J 2002; 16: 1129.
26. Engelbrecht AM, Niesler C, Page C, et al. p38 and JNK have distinct regulatory functions on the development of apoptosis during simulated ischemia and reperfusion in neonatal cardiomyocytes. Basic Res Cardiol 2004; 99: 338.
27. Li Z, Ma Y, Kerr I, et al. Selective inhibition of p38α MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury. Am J Physiol Heart Circ Physiol 2006; 291: H1972.
28. Murayama T, Tanabe M, Matsuda S, et al. JNK (c-jun terminal kinase) and p38 during ischemia reperfusion injury in the small intestine. Transplantation 2006; 81: 1325.
29. Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoietin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69: 1806.
30. Erbayraktar S, Grasso G, Sfacteria A, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 2003; 100: 6741.
31. Wang X, Zhu C, Wang X, et al. The nonerythropoietic asialoerythropoietin protects against neonatal hypoxia-ischemia as potently as erythropoietin. J Neurochem 2004; 91: 900.
32. Li Z, Ma Y, Kerr I, et al. selective inhibition of p38α MAPK improves cardiac function and reduces myocardial apoptosis in rat model of myocardial injury. Am J Physiol Heart Circ Physiol 2006; 291: H1972.
33. Lee JC, Kassis S, Kumar S, et al. p38 mitogen-activated protein kinase inhibitors-mechanism and therapeutic potentials. Phamacol Ther 1999; 82: 389.